Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling.

Zak M, Hanan EJ, Lupardus P, Brown DG, Robinson C, Siu M, Lyssikatos JP, Romero FA, Zhao G, Kellar T, Mendonca R, Ray NC, Goodacre SC, Crackett PH, McLean N, Hurley CA, Yuen PW, Cheng YX, Liu X, Liimatta M, Kohli PB, Nonomiya J, Salmon G, Buckley G, Lloyd J, Gibbons P, Ghilardi N, Kenny JR, Johnson A.

Bioorg Med Chem Lett. 2019 Jun 15;29(12):1522-1531. doi: 10.1016/j.bmcl.2019.04.008. Epub 2019 Apr 4.

PMID:
30981576
2.

Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma.

Dengler HS, Wu X, Peng I, Rinderknecht CH, Kwon Y, Suto E, Kohli PB, Liimatta M, Barrett K, Lloyd J, Cain G, Briggs M, Addo S, Salmon G, Ubhayakar S, Deshmukh G, Shahidi-Latham SK, Quiason-Huynh CM, Jackman J, Liu J, Ray NC, Goodacre SC, Johnson A, McKenzie BS, Lee WP, Zak M, Kenny JR, Ghilardi N.

Sci Transl Med. 2018 Nov 21;10(468). pii: eaao2151. doi: 10.1126/scitranslmed.aao2151.

PMID:
30463918
3.

Scaffold-Hopping Approach To Discover Potent, Selective, and Efficacious Inhibitors of NF-κB Inducing Kinase.

Blaquiere N, Castanedo GM, Burch JD, Berezhkovskiy LM, Brightbill H, Brown S, Chan C, Chiang PC, Crawford JJ, Dong T, Fan P, Feng J, Ghilardi N, Godemann R, Gogol E, Grabbe A, Hole AJ, Hu B, Hymowitz SG, Alaoui Ismaili MH, Le H, Lee P, Lee W, Lin X, Liu N, McEwan PA, McKenzie B, Silvestre HL, Suto E, Sujatha-Bhaskar S, Wu G, Wu LC, Zhang Y, Zhong Z, Staben ST.

J Med Chem. 2018 Aug 9;61(15):6801-6813. doi: 10.1021/acs.jmedchem.8b00678. Epub 2018 Jul 24.

PMID:
29940120
4.

Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.

Crawford JJ, Johnson AR, Misner DL, Belmont LD, Castanedo G, Choy R, Coraggio M, Dong L, Eigenbrot C, Erickson R, Ghilardi N, Hau J, Katewa A, Kohli PB, Lee W, Lubach JW, McKenzie BS, Ortwine DF, Schutt L, Tay S, Wei B, Reif K, Liu L, Wong H, Young WB.

J Med Chem. 2018 Mar 22;61(6):2227-2245. doi: 10.1021/acs.jmedchem.7b01712. Epub 2018 Feb 23.

PMID:
29457982
5.

NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus.

Brightbill HD, Suto E, Blaquiere N, Ramamoorthi N, Sujatha-Bhaskar S, Gogol EB, Castanedo GM, Jackson BT, Kwon YC, Haller S, Lesch J, Bents K, Everett C, Kohli PB, Linge S, Christian L, Barrett K, Jaochico A, Berezhkovskiy LM, Fan PW, Modrusan Z, Veliz K, Townsend MJ, DeVoss J, Johnson AR, Godemann R, Lee WP, Austin CD, McKenzie BS, Hackney JA, Crawford JJ, Staben ST, Alaoui Ismaili MH, Wu LC, Ghilardi N.

Nat Commun. 2018 Jan 12;9(1):179. doi: 10.1038/s41467-017-02672-0.

6.

Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model.

Liang J, Van Abbema A, Balazs M, Barrett K, Berezhkovsky L, Blair WS, Chang C, Delarosa D, DeVoss J, Driscoll J, Eigenbrot C, Goodacre S, Ghilardi N, MacLeod C, Johnson A, Bir Kohli P, Lai Y, Lin Z, Mantik P, Menghrajani K, Nguyen H, Peng I, Sambrone A, Shia S, Smith J, Sohn S, Tsui V, Ultsch M, Williams K, Wu LC, Yang W, Zhang B, Magnuson S.

Bioorg Med Chem Lett. 2017 Sep 15;27(18):4370-4376. doi: 10.1016/j.bmcl.2017.08.022. Epub 2017 Aug 12.

PMID:
28830649
7.

T Cell-Derived IL-10 Impairs Host Resistance to Mycobacterium tuberculosis Infection.

Moreira-Teixeira L, Redford PS, Stavropoulos E, Ghilardi N, Maynard CL, Weaver CT, Freitas do Rosário AP, Wu X, Langhorne J, O'Garra A.

J Immunol. 2017 Jul 15;199(2):613-623. doi: 10.4049/jimmunol.1601340. Epub 2017 Jun 5.

8.

IL-27 Directly Enhances Germinal Center B Cell Activity and Potentiates Lupus in Sanroque Mice.

Vijayan D, Mohd Redzwan N, Avery DT, Wirasinha RC, Brink R, Walters G, Adelstein S, Kobayashi M, Gray P, Elliott M, Wong M, King C, Vinuesa CG, Ghilardi N, Ma CS, Tangye SG, Batten M.

J Immunol. 2016 Oct 15;197(8):3008-3017. Epub 2016 Sep 12.

9.

Blockade of interleukin-27 signaling reduces GVHD in mice by augmenting Treg reconstitution and stabilizing Foxp3 expression.

Belle L, Agle K, Zhou V, Yin-Yuan C, Komorowski R, Eastwood D, Logan B, Sun J, Ghilardi N, Cua D, Williams CB, Gaignage M, Marillier R, van Snick J, Drobyski WR.

Blood. 2016 Oct 20;128(16):2068-2082. doi: 10.1182/blood-2016-02-698241. Epub 2016 Aug 3.

10.

Nonselective inhibition of the epigenetic transcriptional regulator BET induces marked lymphoid and hematopoietic toxicity in mice.

Lee DU, Katavolos P, Palanisamy G, Katewa A, Sioson C, Corpuz J, Pang J, DeMent K, Choo E, Ghilardi N, Diaz D, Danilenko DM.

Toxicol Appl Pharmacol. 2016 Jun 1;300:47-54. doi: 10.1016/j.taap.2016.03.013. Epub 2016 Apr 11.

PMID:
27078884
11.

Arteriolar Diameters in Glaucomatous Eyes with Single-Hemifield Damage.

Russo A, Costagliola C, Rizzoni D, Ghilardi N, Turano R, Semeraro F.

Optom Vis Sci. 2016 May;93(5):504-9. doi: 10.1097/OPX.0000000000000822.

PMID:
26840920
12.

Inhibition of the kinase ITK in a mouse model of asthma reduces cell death and fails to inhibit the inflammatory response.

Sun Y, Peng I, Webster JD, Suto E, Lesch J, Wu X, Senger K, Francis G, Barrett K, Collier JL, Burch JD, Zhou M, Chen Y, Chan C, Eastham-Anderson J, Ngu H, Li O, Staton T, Havnar C, Jaochico A, Jackman J, Jeet S, Riol-Blanco L, Wu LC, Choy DF, Arron JR, McKenzie BS, Ghilardi N, Ismaili MH, Pei Z, DeVoss J, Austin CD, Lee WP, Zarrin AA.

Sci Signal. 2015 Dec 1;8(405):ra122. doi: 10.1126/scisignal.aab0949.

PMID:
26628680
13.

Interleukin 27R regulates CD4+ T cell phenotype and impacts protective immunity during Mycobacterium tuberculosis infection.

Torrado E, Fountain JJ, Liao M, Tighe M, Reiley WW, Lai RP, Meintjes G, Pearl JE, Chen X, Zak DE, Thompson EG, Aderem A, Ghilardi N, Solache A, McKinstry KK, Strutt TM, Wilkinson RJ, Swain SL, Cooper AM.

J Exp Med. 2015 Aug 24;212(9):1449-63. doi: 10.1084/jem.20141520. Epub 2015 Aug 17.

14.

Homeostatic IL-23 receptor signaling limits Th17 response through IL-22-mediated containment of commensal microbiota.

Shih VF, Cox J, Kljavin NM, Dengler HS, Reichelt M, Kumar P, Rangell L, Kolls JK, Diehl L, Ouyang W, Ghilardi N.

Proc Natl Acad Sci U S A. 2014 Sep 23;111(38):13942-7. doi: 10.1073/pnas.1323852111. Epub 2014 Sep 8.

15.

Oral-resident natural Th17 cells and γδ T cells control opportunistic Candida albicans infections.

Conti HR, Peterson AC, Brane L, Huppler AR, Hernández-Santos N, Whibley N, Garg AV, Simpson-Abelson MR, Gibson GA, Mamo AJ, Osborne LC, Bishu S, Ghilardi N, Siebenlist U, Watkins SC, Artis D, McGeachy MJ, Gaffen SL.

J Exp Med. 2014 Sep 22;211(10):2075-84. doi: 10.1084/jem.20130877. Epub 2014 Sep 8.

16.

Type I IFN induces IL-10 production in an IL-27-independent manner and blocks responsiveness to IFN-γ for production of IL-12 and bacterial killing in Mycobacterium tuberculosis-infected macrophages.

McNab FW, Ewbank J, Howes A, Moreira-Teixeira L, Martirosyan A, Ghilardi N, Saraiva M, O'Garra A.

J Immunol. 2014 Oct 1;193(7):3600-12. doi: 10.4049/jimmunol.1401088. Epub 2014 Sep 3.

17.

The adaptor CARD9 is required for adaptive but not innate immunity to oral mucosal Candida albicans infections.

Bishu S, Hernández-Santos N, Simpson-Abelson MR, Huppler AR, Conti HR, Ghilardi N, Mamo AJ, Gaffen SL.

Infect Immun. 2014 Mar;82(3):1173-80. doi: 10.1128/IAI.01335-13. Epub 2013 Dec 30.

18.

Cognitive dysfunction and age-related macular degeneration.

Rozzini L, Riva M, Ghilardi N, Facchinetti P, Forbice E, Semeraro F, Padovani A.

Am J Alzheimers Dis Other Demen. 2014 May;29(3):256-62. doi: 10.1177/1533317513517032. Epub 2013 Dec 26.

PMID:
24370621
19.

Intestinal lamina propria dendritic cells maintain T cell homeostasis but do not affect commensalism.

Welty NE, Staley C, Ghilardi N, Sadowsky MJ, Igyártó BZ, Kaplan DH.

J Exp Med. 2013 Sep 23;210(10):2011-24. doi: 10.1084/jem.20130728. Epub 2013 Sep 9.

20.

A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors.

Sohn SJ, Barrett K, Van Abbema A, Chang C, Kohli PB, Kanda H, Smith J, Lai Y, Zhou A, Zhang B, Yang W, Williams K, Macleod C, Hurley CA, Kulagowski JJ, Lewin-Koh N, Dengler HS, Johnson AR, Ghilardi N, Zak M, Liang J, Blair WS, Magnuson S, Wu LC.

J Immunol. 2013 Sep 1;191(5):2205-16. doi: 10.4049/jimmunol.1202859. Epub 2013 Jul 26.

21.

2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitors.

Siu M, Pastor R, Liu W, Barrett K, Berry M, Blair WS, Chang C, Chen JZ, Eigenbrot C, Ghilardi N, Gibbons P, He H, Hurley CA, Kenny JR, Cyrus Khojasteh S, Le H, Lee L, Lyssikatos JP, Magnuson S, Pulk R, Tsui V, Ultsch M, Xiao Y, Zhu BY, Sampath D.

Bioorg Med Chem Lett. 2013 Sep 1;23(17):5014-21. doi: 10.1016/j.bmcl.2013.06.008. Epub 2013 Jun 15.

PMID:
23870430
22.

Lead identification of novel and selective TYK2 inhibitors.

Liang J, Tsui V, Van Abbema A, Bao L, Barrett K, Beresini M, Berezhkovskiy L, Blair WS, Chang C, Driscoll J, Eigenbrot C, Ghilardi N, Gibbons P, Halladay J, Johnson A, Kohli PB, Lai Y, Liimatta M, Mantik P, Menghrajani K, Murray J, Sambrone A, Xiao Y, Shia S, Shin Y, Smith J, Sohn S, Stanley M, Ultsch M, Zhang B, Wu LC, Magnuson S.

Eur J Med Chem. 2013 Sep;67:175-87. doi: 10.1016/j.ejmech.2013.03.070. Epub 2013 May 14.

PMID:
23867602
23.

Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors.

Liang J, van Abbema A, Balazs M, Barrett K, Berezhkovsky L, Blair W, Chang C, Delarosa D, DeVoss J, Driscoll J, Eigenbrot C, Ghilardi N, Gibbons P, Halladay J, Johnson A, Kohli PB, Lai Y, Liu Y, Lyssikatos J, Mantik P, Menghrajani K, Murray J, Peng I, Sambrone A, Shia S, Shin Y, Smith J, Sohn S, Tsui V, Ultsch M, Wu LC, Xiao Y, Yang W, Young J, Zhang B, Zhu BY, Magnuson S.

J Med Chem. 2013 Jun 13;56(11):4521-36. doi: 10.1021/jm400266t. Epub 2013 May 29.

PMID:
23668484
24.

Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.

Zak M, Hurley CA, Ward SI, Bergeron P, Barrett K, Balazs M, Blair WS, Bull R, Chakravarty P, Chang C, Crackett P, Deshmukh G, DeVoss J, Dragovich PS, Eigenbrot C, Ellwood C, Gaines S, Ghilardi N, Gibbons P, Gradl S, Gribling P, Hamman C, Harstad E, Hewitt P, Johnson A, Johnson T, Kenny JR, Koehler MF, Bir Kohli P, Labadie S, Lee WP, Liao J, Liimatta M, Mendonca R, Narukulla R, Pulk R, Reeve A, Savage S, Shia S, Steffek M, Ubhayakar S, van Abbema A, Aliagas I, Avitabile-Woo B, Xiao Y, Yang J, Kulagowski JJ.

J Med Chem. 2013 Jun 13;56(11):4764-85. doi: 10.1021/jm4004895. Epub 2013 May 31.

PMID:
23659214
25.

Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1.

Hurley CA, Blair WS, Bull RJ, Chang C, Crackett PH, Deshmukh G, Dyke HJ, Fong R, Ghilardi N, Gibbons P, Hewitt PR, Johnson A, Johnson T, Kenny JR, Kohli PB, Kulagowski JJ, Liimatta M, Lupardus PJ, Maxey RJ, Mendonca R, Narukulla R, Pulk R, Ubhayakar S, van Abbema A, Ward SI, Waszkowycz B, Zak M.

Bioorg Med Chem Lett. 2013 Jun 15;23(12):3592-8. doi: 10.1016/j.bmcl.2013.04.018. Epub 2013 Apr 17.

PMID:
23642482
26.

Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.

Labadie S, Dragovich PS, Barrett K, Blair WS, Bergeron P, Chang C, Deshmukh G, Eigenbrot C, Ghilardi N, Gibbons P, Hurley CA, Johnson A, Kenny JR, Kohli PB, Kulagowski JJ, Liimatta M, Lupardus PJ, Mendonca R, Murray JM, Pulk R, Shia S, Steffek M, Ubhayakar S, Ultsch M, van Abbema A, Ward S, Zak M.

Bioorg Med Chem Lett. 2012 Dec 15;22(24):7627-33. doi: 10.1016/j.bmcl.2012.10.008. Epub 2012 Oct 11.

PMID:
23107482
27.

Bystanders not so innocent after all.

Batten M, Ghilardi N.

Immunity. 2012 Jun 29;36(6):901-3. doi: 10.1016/j.immuni.2012.06.001.

28.

Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.

Zak M, Mendonca R, Balazs M, Barrett K, Bergeron P, Blair WS, Chang C, Deshmukh G, Devoss J, Dragovich PS, Eigenbrot C, Ghilardi N, Gibbons P, Gradl S, Hamman C, Hanan EJ, Harstad E, Hewitt PR, Hurley CA, Jin T, Johnson A, Johnson T, Kenny JR, Koehler MF, Bir Kohli P, Kulagowski JJ, Labadie S, Liao J, Liimatta M, Lin Z, Lupardus PJ, Maxey RJ, Murray JM, Pulk R, Rodriguez M, Savage S, Shia S, Steffek M, Ubhayakar S, Ultsch M, van Abbema A, Ward SI, Xiao L, Xiao Y.

J Med Chem. 2012 Jul 12;55(13):6176-93. doi: 10.1021/jm300628c. Epub 2012 Jun 28.

PMID:
22698084
29.

Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.

Kulagowski JJ, Blair W, Bull RJ, Chang C, Deshmukh G, Dyke HJ, Eigenbrot C, Ghilardi N, Gibbons P, Harrison TK, Hewitt PR, Liimatta M, Hurley CA, Johnson A, Johnson T, Kenny JR, Bir Kohli P, Maxey RJ, Mendonca R, Mortara K, Murray J, Narukulla R, Shia S, Steffek M, Ubhayakar S, Ultsch M, van Abbema A, Ward SI, Waszkowycz B, Zak M.

J Med Chem. 2012 Jun 28;55(12):5901-21. doi: 10.1021/jm300438j. Epub 2012 Jun 11.

PMID:
22591402
30.

Opposing consequences of IL-23 signaling mediated by innate and adaptive cells in chemically induced colitis in mice.

Cox JH, Kljavin NM, Ota N, Leonard J, Roose-Girma M, Diehl L, Ouyang W, Ghilardi N.

Mucosal Immunol. 2012 Jan;5(1):99-109. doi: 10.1038/mi.2011.54. Epub 2011 Nov 16.

PMID:
22089030
31.

Functional studies on the IBD susceptibility gene IL23R implicate reduced receptor function in the protective genetic variant R381Q.

Pidasheva S, Trifari S, Phillips A, Hackney JA, Ma Y, Smith A, Sohn SJ, Spits H, Little RD, Behrens TW, Honigberg L, Ghilardi N, Clark HF.

PLoS One. 2011;6(10):e25038. doi: 10.1371/journal.pone.0025038. Epub 2011 Oct 12.

32.

IL-27 promotes T cell-dependent colitis through multiple mechanisms.

Cox JH, Kljavin NM, Ramamoorthi N, Diehl L, Batten M, Ghilardi N.

J Exp Med. 2011 Jan 17;208(1):115-23. doi: 10.1084/jem.20100410. Epub 2010 Dec 20.

33.

IL-27 supports germinal center function by enhancing IL-21 production and the function of T follicular helper cells.

Batten M, Ramamoorthi N, Kljavin NM, Ma CS, Cox JH, Dengler HS, Danilenko DM, Caplazi P, Wong M, Fulcher DA, Cook MC, King C, Tangye SG, de Sauvage FJ, Ghilardi N.

J Exp Med. 2010 Dec 20;207(13):2895-906. doi: 10.1084/jem.20100064. Epub 2010 Nov 22.

34.

A mouse knockout library for secreted and transmembrane proteins.

Tang T, Li L, Tang J, Li Y, Lin WY, Martin F, Grant D, Solloway M, Parker L, Ye W, Forrest W, Ghilardi N, Oravecz T, Platt KA, Rice DS, Hansen GM, Abuin A, Eberhart DE, Godowski P, Holt KH, Peterson A, Zambrowicz BP, de Sauvage FJ.

Nat Biotechnol. 2010 Jul;28(7):749-55. doi: 10.1038/nbt.1644. Epub 2010 Jun 20.

PMID:
20562862
35.

Negative regulation of autoimmune demyelination by the inhibitory receptor CLM-1.

Xi H, Katschke KJ Jr, Helmy KY, Wark PA, Kljavin N, Clark H, Eastham-Anderson J, Shek T, Roose-Girma M, Ghilardi N, van Lookeren Campagne M.

J Exp Med. 2010 Jan 18;207(1):7-16. doi: 10.1084/jem.20091508. Epub 2009 Dec 28.

36.

Interleukin (IL)-23 mediates Toxoplasma gondii-induced immunopathology in the gut via matrixmetalloproteinase-2 and IL-22 but independent of IL-17.

Muñoz M, Heimesaat MM, Danker K, Struck D, Lohmann U, Plickert R, Bereswill S, Fischer A, Dunay IR, Wolk K, Loddenkemper C, Krell HW, Libert C, Lund LR, Frey O, Hölscher C, Iwakura Y, Ghilardi N, Ouyang W, Kamradt T, Sabat R, Liesenfeld O.

J Exp Med. 2009 Dec 21;206(13):3047-59. doi: 10.1084/jem.20090900. Epub 2009 Dec 7.

37.

IL-23 is required for protection against systemic infection with Listeria monocytogenes.

Meeks KD, Sieve AN, Kolls JK, Ghilardi N, Berg RE.

J Immunol. 2009 Dec 15;183(12):8026-34. doi: 10.4049/jimmunol.0901588.

38.

Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis.

Hofmann I, Stover EH, Cullen DE, Mao J, Morgan KJ, Lee BH, Kharas MG, Miller PG, Cornejo MG, Okabe R, Armstrong SA, Ghilardi N, Gould S, de Sauvage FJ, McMahon AP, Gilliland DG.

Cell Stem Cell. 2009 Jun 5;4(6):559-67. doi: 10.1016/j.stem.2009.03.016.

39.

Cutting edge: IL-27 is a potent inducer of IL-10 but not FoxP3 in murine T cells.

Batten M, Kljavin NM, Li J, Walter MJ, de Sauvage FJ, Ghilardi N.

J Immunol. 2008 Mar 1;180(5):2752-6.

40.

Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens.

Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q, Abbas AR, Modrusan Z, Ghilardi N, de Sauvage FJ, Ouyang W.

Nat Med. 2008 Mar;14(3):282-9. doi: 10.1038/nm1720. Epub 2008 Feb 10.

PMID:
18264109
41.

Targeting the development and effector functions of TH17 cells.

Ghilardi N, Ouyang W.

Semin Immunol. 2007 Dec;19(6):383-93. Epub 2008 Jan 14. Review.

PMID:
18083530
42.

Regulation of myeloid progenitor cell proliferation/survival by IL-31 receptor and IL-31.

Broxmeyer HE, Li J, Hangoc G, Cooper S, Tao W, Mantel C, Graham-Evans B, Ghilardi N, de Sauvage FJ.

Exp Hematol. 2007 Apr;35(4 Suppl 1):78-86.

43.

IL-31-IL-31R interactions negatively regulate type 2 inflammation in the lung.

Perrigoue JG, Li J, Zaph C, Goldschmidt M, Scott P, de Sauvage FJ, Pearce EJ, Ghilardi N, Artis D.

J Exp Med. 2007 Mar 19;204(3):481-7. Epub 2007 Mar 12.

44.

The biology and therapeutic potential of interleukin 27.

Batten M, Ghilardi N.

J Mol Med (Berl). 2007 Jul;85(7):661-72. Epub 2007 Feb 10. Review.

PMID:
17294231
45.

Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells.

Batten M, Li J, Yi S, Kljavin NM, Danilenko DM, Lucas S, Lee J, de Sauvage FJ, Ghilardi N.

Nat Immunol. 2006 Sep;7(9):929-36. Epub 2006 Aug 13.

PMID:
16906167
46.

Interleukin 12p40 is required for dendritic cell migration and T cell priming after Mycobacterium tuberculosis infection.

Khader SA, Partida-Sanchez S, Bell G, Jelley-Gibbs DM, Swain S, Pearl JE, Ghilardi N, Desauvage FJ, Lund FE, Cooper AM.

J Exp Med. 2006 Jul 10;203(7):1805-15. Epub 2006 Jul 3.

47.

CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens.

Helmy KY, Katschke KJ Jr, Gorgani NN, Kljavin NM, Elliott JM, Diehl L, Scales SJ, Ghilardi N, van Lookeren Campagne M.

Cell. 2006 Mar 10;124(5):915-27.

48.

Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae.

Happel KI, Dubin PJ, Zheng M, Ghilardi N, Lockhart C, Quinton LJ, Odden AR, Shellito JE, Bagby GJ, Nelson S, Kolls JK.

J Exp Med. 2005 Sep 19;202(6):761-9. Epub 2005 Sep 12.

49.

IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available.

Khader SA, Pearl JE, Sakamoto K, Gilmartin L, Bell GK, Jelley-Gibbs DM, Ghilardi N, deSauvage F, Cooper AM.

J Immunol. 2005 Jul 15;175(2):788-95.

50.

IL-27 signaling compromises control of bacterial growth in mycobacteria-infected mice.

Pearl JE, Khader SA, Solache A, Gilmartin L, Ghilardi N, deSauvage F, Cooper AM.

J Immunol. 2004 Dec 15;173(12):7490-6.

Supplemental Content

Loading ...
Support Center